Phase II study of cyclophosphamide (C), epirubicin (E), oncovin (O), prednisone (P), methotrexate (M) + leucovorin and bleomycin (B) (CEOP-MB) in intermediate and high grade non-Hodgkin lymphomas.
Thirty-five patients with non-Hodgkin lymphoma of intermediate or high-grade histology were treated with cyclophosphamide, epirubicin, vincristine, prednisone, methotrexate plus leucovorin and bleomycin (CEOP-MB). The complete response rate was 66%. The relapse rate of these complete responders was 39%. After a median follow-up of 3 years the median duration of complete response was 23 months and the median survival of the complete responders 52 months. The median survival of the entire group was 35.5 months. The toxicity was acceptable with no cases of congestive heart failure and no toxic deaths. Epirubicin appears to have a better therapeutic index than doxorubicin in aggressive treatment protocols in advanced non-Hodgkin lymphomas.
Wils
J
J
Laurentius Hospital, Roermond, The Netherlands.
Smeets
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate